Atara Biotherapeutics Investors Have Until May 22 to Seek Lead Plaintiff Role

Lawsuit alleges manufacturing issues and study design flaws jeopardized FDA approval for Atara's lead drug candidate

Apr. 7, 2026 at 10:36pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex pharmaceutical manufacturing equipment and machinery, bathed in harsh industrial lighting, conceptually representing the technical challenges and regulatory scrutiny facing Atara Biotherapeutics.The manufacturing issues that plagued Atara Biotherapeutics' drug candidate have exposed the company to heightened regulatory scrutiny and jeopardized its clinical trials.NYC Today

A securities fraud class action lawsuit has been filed on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. The lawsuit alleges that Atara made misleading statements about the regulatory prospects of its lead drug candidate, tabelecleucel, which was ultimately rejected by the FDA due to manufacturing problems and study design flaws.

Why it matters

This case highlights the risks investors face when a biotech company's lead drug candidate encounters manufacturing and clinical trial issues that derail the path to regulatory approval. Atara's stock price plunged over 50% on the news of the FDA's rejection, underscoring the high stakes for investors in the volatile pharmaceutical industry.

The details

The lawsuit alleges that Atara misled investors by overstating the regulatory prospects of tabelecleucel, its lead drug candidate for treating certain cancers. Specifically, the complaint claims that (1) manufacturing problems at a third-party facility and design flaws in the ALLELE clinical trial made it unlikely the FDA would approve tabelecleucel's Biologics License Application (BLA); (2) these issues subjected Atara to heightened regulatory scrutiny and jeopardized its ongoing trials; and (3) all of this would have a significant negative impact on Atara's business.

  • On January 16, 2025, Atara announced receiving a Complete Response Letter (CRL) from the FDA regarding the tabelecleucel BLA, citing manufacturing issues at a third-party facility.
  • On January 21, 2025, Atara announced the FDA had placed a clinical hold on its active Investigational New Drug (IND) applications due to 'inadequately addressed GMP compliance issues' at the manufacturing facility.
  • On January 12, 2026, Atara announced receiving another CRL from the FDA, stating the ALLELE trial was 'no longer considered to be adequate to provide evidence of effectiveness' for tabelecleucel.

The players

Atara Biotherapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for serious diseases.

Kirby McInerney LLP

A New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Got photos? Submit your photos here. ›

What they’re saying

“If you have suffered a loss on your Atara Biotherapeutics, Inc. ('Atara' or the 'Company') (NASDAQ:ATRA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.”

— Lauren Molinaro, Attorney, Kirby McInerney LLP

What’s next

Investors have until May 22, 2026 to apply to the court to be appointed as lead plaintiff in the class action lawsuit.

The takeaway

This case highlights the risks biotech investors face when a company's lead drug candidate encounters manufacturing and clinical trial issues that derail the path to regulatory approval, leading to significant stock price declines.